Horváth Gábor, Gerlei Zsuzsanna, Gervain Judit, Lengyel Gabriella, Makara Mihály, Pár Alajos, Rókusz László, Szalay Ferenc, Tornai István, Werling Klára, Hunyady Béla
Hepatológiai Szakrendelés Budapest és Budai Hepatológiai Centrum, Szent János Kórház és Észak-budai Egyesített Kórházak Budapest, Egry József u. 1-3., 1111.
Transzplantációs és Sebészeti Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest.
Orv Hetil. 2018 Feb;159(Suppl 1):24-37. doi: 10.1556/650.2018.31004.
Diagnosis and treatment of hepatitis B virus (HBV) and hepatitis D virus infection mean for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms from 22 September 2017 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0,5-0,7%. The indications of treatment are based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for a cost-effective approach, the guideline stresses the importance of quick and detailed virologic evaluations, the applicability of transient elastography as an acceptable alternative of liver biopsy in this regard as well as the relevance of appropriate consistent follow-up schedule for viral response during therapy. The first choice of therapy in chronic HBV infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Lamivudine is no longer the first choice; patients currently taking lamivudine must switch if the response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection. Orv Hetil. 2018; 159(Suppl 1): 24-37.
乙型肝炎病毒（HBV）和丁型肝炎病毒感染的诊断与治疗，意味着患者能够维持工作能力、提高生活质量、预防癌症并延长预期寿命，同时社会也能从消除病毒进一步传播的机会以及降低严重并发症的总体成本中受益。本指南阐述了参与这些疾病治疗的医生于2017年9月22日达成共识会议所制定的治疗算法。匈牙利普通人群中HBV感染的患病率为0.5%-0.7%。治疗指征基于病毒学检查（包括病毒核酸测定）、疾病活动度和分期的测定（包括生化、病理和/或非侵入性方法），并排除禁忌证。为避免不必要的副作用并采用具有成本效益的方法，本指南强调快速且详细的病毒学评估的重要性、瞬时弹性成像在这方面作为肝活检可接受替代方法的适用性以及治疗期间对病毒反应进行适当持续随访计划的相关性。慢性HBV感染的首选治疗方法可以是聚乙二醇化干扰素治疗48周，或持续使用恩替卡韦或替诺福韦治疗。后两者在乙肝表面抗原血清学转换后必须至少持续使用12个月。拉米夫定不再是首选；目前正在服用拉米夫定的患者如果反应不佳必须换药。强烈建议对服用免疫抑制药物的患者进行适当治疗。推荐采用基于聚乙二醇化干扰素的疗法治疗合并丁型肝炎感染。《匈牙利医学周报》。2018年；159（增刊1）：24 - 37。
